NCT03463512已完成3 期
Multicenter, Open-label, Controlled, Randomized Clinical Study to Evaluate the Efficacy and Safety of Racecadotril in Infants, Children and Adolescents With Acute Diarrhea
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Abbott
- 入组人数
- 124
- 试验地点
- 1
- 主要终点
- Duration of Diarrhea (Hours) Between the Start of Treatment Until Last Diarrheal/Watery Stool Before Recovery or End of Study Treatment (Treatment Duration Maximal 5 Days)
研究概览
简要总结
Multicenter, open-label, controlled, randomized clinical study to evaluate the efficacy and safety of Racecadotril in infants, children and adolescents with acute diarrhea
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 3 Months 至 17 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed informed consent from one of the parent(s)/caregiver(s) or subject informed assent
- •Children and adolescents, both genders, age from 3 months to < 18 years of age
- •Confirmed diagnosis of acute diarrhea (defined as the passage of three or more unformed or liquid stools within the last 24 hours and lasting for less than three days)
- •Females of child-bearing potential should agree to continue using a medically acceptable method of birth control throughout the study and for 30 days immediately after the last dose of study drug. Medically acceptable methods of birth control include bilateral tubal ligation or the use of either a contraceptive implant, a contraceptive injection, an intrauterine device, or an oral contraceptive taken within the past three months where the subject agrees to continue using during the study or to adopt another birth control method, or a double-barrier method which consists of a combination of any two of the following: diaphragm, cervical cap, condom, or spermicide
排除标准
- •Known allergy to Racecadotril or any of its ingredients
- •Subjects suffering from renal or hepatic impairment
- •Subjects who need treatment for diarrhea other than ORS alone
- •Subjects with fever > 39 degrees Celsius
- •Subjects with bloody and/or purulent stools
- •Subjects suffering from antibiotic-associated diarrhea, chronic diarrhea or iatrogenic diarrhea
- •Subjects with alternating bouts of diarrhea and constipation
- •Diarrhea due to exacerbation of chronic gastrointestinal diseases such as irritable bowel syndrome, inflammatory bowel disease or pancreatic exocrine insufficiency
- •Cystic fibrosis or coeliac disease
- •Subjects suffering from prolonged or uncontrolled vomiting
- •Subjects with rare hereditary problems of fructose or galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption syndrome or sucrase isomaltase insufficiency or primary or secondary lactase insufficiency
- •Subjects having received antibiotic treatment at any time within 30 days prior to inclusion into the study
- •Subjects having received antidiarrheal drugs 48 hours prior to inclusion into the study
- •Subjects with severe dehydration required for intravenous/parenteral rehydration
- •Subjects who have reported angioedema with angiotensin converting enzyme inhibitors (such as captopril, enalapril, lisinopril, perindopril, ramipril)
- •Subjects with combined diseases or medical situations that would prevent to be enrolled depending in the judgment of the investigator
- •Intake of experimental drug within 30 days prior to study start
- •Subjects with contraindications to ORS or for whom warnings/precautions of ORS apply
- •Adolescents (≥ 60 kg) not able to swallow capsules
- •Pregnancy and lactation
研究组 & 干预措施
Racecadotril plus standard treatment oral rehydration solution
Experimental
干预措施: Racecadotril plus ORS (Drug)
ORS (standard treatment)
Active Comparator
干预措施: ORS (Drug)
结局指标
主要结局
Duration of Diarrhea (Hours) Between the Start of Treatment Until Last Diarrheal/Watery Stool Before Recovery or End of Study Treatment (Treatment Duration Maximal 5 Days)
时间窗: 5 days
Duration of diarrhea is defined by date and time of the evacuation of the final diarrheal stool derived from the daily diary. Log-rank test was performed with a p-value \< 0.0001
次要结局
- Number of Recovered Subjects Per Treatment Group.(5 days)
- Number of Recovered Subjects as Defined by Global Physician Assessment of Success at the End of Treatment(5 days)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
3 期
Bendamustine and Rituximab With or Without Orelabrutinib in MCL TreatmentMantle Cell Lymphoma (MCL)NCT06496308Ruijin Hospital78
已完成
4 期
Safety and Efficacy of Mecobalamin Injection in Peripheral Neuropathies Patients (Study JGAZSY091109)Peripheral NeuropathyNCT01192113Eisai Co., Ltd.1,072
终止
2 期
Safety and Efficacy of Ampligen in the Treatment of HIV Patients Failing HAARTHIV SeropositivityHIV InfectionNCT00035581AIM ImmunoTech Inc.16
招募中
2 期
Clinical Study of Reduced-dose Pomalidomide and Cyclophosphamide Combined With Dexamethasone in the Treatment of Patients With Debilitating RRMMMultiple Myeloma in RelapseNCT06255847Shanxi Bethune Hospital43
Unknown
2 期
To Evaluate the Efficacy and Safety of CAN008 Combined With Re-irradiation (rRT) for Treating Patients With Recurrent Glioblastoma (GBM)GBMNCT03746288CANbridge Life Sciences Ltd.60